Rule lifecycle · DOCKET:Docket No. FDA-2026-N-0008
Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal
Health and Human Services Department, Food and Drug Administration — observed across 3 documents over 42 days. Use the source documents below before deciding whether this affects your business.
In plain English
The FDA is renewing its Dermatologic and Ophthalmic Drugs Advisory Committee, a panel that advises on approving skin and eye medications. If you develop skin or eye care drugs or devices, mark your calendar for this committee's public meetings where you can share data and feedback about your products.
First seen
Aug 20, 2026
Last seen
Oct 1, 2026
Latest stage
Notice
PRORULE → RULE
—
Stage timeline
Notice·Aug 20, 2026·91 FR 53882
Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal
#2026-16999
Notice·Oct 1, 2026·91 FR 62520
Advisory Committee; Antimicrobial Drugs Advisory Committee; Renewal
#2026-20142
Notice·Oct 1, 2026·91 FR 62530
Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal
#2026-20141